Lazertinib with amivantamab and platinum-based chemotherapy for EGFR-mutated locally advanced or metastatic non-small-cell lung cancer after osimertinib failure

Lazertinib with amivantamab and platinum-based chemotherapy are currently in clinical development for patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. NSCLC is the most common type of lung cancer. Metastatic and advanced cancer means that the cancer has spread and where curative treatment with surgery is unsuitable. EGFR is a protein found on certain types of cells that is involved in cell signalling pathways that control cell division and survival. Mutations in this protein can cause increased cell division resulting in tumour growth. However, there is a lack of effective treatments for this population group.